113 related articles for article (PubMed ID: 7318129)
21. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.
Wolff SN; Johnson DH; Hainsworth JD; Greco FA
J Clin Oncol; 1984 Apr; 2(4):271-4. PubMed ID: 6368760
[TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies.
Murren JR; DiStasio SA; Lorico A; McKeon A; Zuhowski EG; Egorin MJ; Sartorelli AC; Rappa G
Cancer J; 2000; 6(4):256-65. PubMed ID: 11038146
[TBL] [Abstract][Full Text] [Related]
23. Chronic daily administration of oral etoposide--a phase I trial.
Hainsworth JD; Johnson DH; Frazier SR; Greco FA
J Clin Oncol; 1989 Mar; 7(3):396-401. PubMed ID: 2918334
[TBL] [Abstract][Full Text] [Related]
24. Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer.
Creagan ET; Eagan RT; Kvols LK
Oncology; 1981; 38(5):260-1. PubMed ID: 7196561
[TBL] [Abstract][Full Text] [Related]
25. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
26. Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials Group.
Paredes J; Kahn JO; Tong WP; Feldstein ML; Lin S; Bennett JM; Metroka CE; Ratner L; Krown SE
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jun; 9(2):138-44. PubMed ID: 7749790
[TBL] [Abstract][Full Text] [Related]
27. [Etoposide: VP-16].
Dicato M
Bull Soc Sci Med Grand Duche Luxemb; 1982; 119(2):15-8. PubMed ID: 7160031
[No Abstract] [Full Text] [Related]
28. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
Hainsworth JD; Spigel DR; Litchy S; Greco FA
J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
[TBL] [Abstract][Full Text] [Related]
29. Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
Gockerman JP; Bartolucci AA; Nelson MO; Silberman H; Velez-Garcia E; Stein R
Cancer Treat Rep; 1986 Jun; 70(6):801-2. PubMed ID: 3524829
[No Abstract] [Full Text] [Related]
30. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
31. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.
Crivellari D; Veronesi A; Magri MD; Tirelli U; Comoretto R; Barzan L; Caruso G; Carbone A; Grigoletto E
Tumori; 1985 Oct; 71(5):499-500. PubMed ID: 4060251
[TBL] [Abstract][Full Text] [Related]
34. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
[TBL] [Abstract][Full Text] [Related]
35. [Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer].
Cavalli F; Jungi WF; Brunner KW
Onkologie; 1981 Apr; 4(2):80-3. PubMed ID: 7022286
[TBL] [Abstract][Full Text] [Related]
36. Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.
Nissen NI; Hansen HH; Pedersen H; Stroyer I; Dombernowsky P; Hessellund M
Cancer Chemother Rep; 1975; 59(5):1027-9. PubMed ID: 1106845
[No Abstract] [Full Text] [Related]
37. Phase II trial of etoposide in advanced prostate cancer.
Trump DL; Loprinzi CL
Cancer Treat Rep; 1984 Sep; 68(9):1195-6. PubMed ID: 6478456
[No Abstract] [Full Text] [Related]
38. Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide.
Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E; Zipoli T; Gonzalves L
J Infus Chemother; 1996; 6(1):43-6. PubMed ID: 8748007
[TBL] [Abstract][Full Text] [Related]
39. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of etoposide in adenocarcinomas of the upper gastrointestinal tract.
Kelsen DP; Magill GB; Cheng E; Dukeman M; Sordillo P; Heelan R; Yagoda A
Cancer Treat Rep; 1983 May; 67(5):509-10. PubMed ID: 6850667
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
